TY - JOUR
KW - SGLT-2 inhibitor
KW - Lung cancer
KW - pharmacoepidemiology
KW - Type 2 diabetes
AU - S. Shapiro
AU - H. Yin
AU - O. H. Y. Yu
AU - L. Azoulay
AD - Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
Division of Endocrinology, Jewish General Hospital, Montreal, Quebec, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.
AN - 38477518
BT - Br J Clin Pharmacol
DO - 10.1111/bcp.16039
DP - NLM
ET - 2024/03/13
LA - eng
N1 - 1365-2125
Shapiro, Samantha B
Orcid: 0000-0002-7957-508x
Yin, Hui
Yu, Oriana H Y
Azoulay, Laurent
Orcid: 0000-0001-5162-3556
FDN-143328/CAPMC/CIHR/Canada
Journal Article
England
Br J Clin Pharmacol. 2024 Mar 13. doi: 10.1111/bcp.16039.
PY - 2024
SN - 0306-5251
T2 - Br J Clin Pharmacol
TI - Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
ER -